Osteomyelitis Due To Staphylococcus Aureus — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for osteomyelitis due to staphylococcus aureus. 10 active patents protecting 3 drugs from 3+ originators. First major cliff: 2035. Daily refresh.

3
Approved drugs
10
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Osteomyelitis Due To Staphylococcus Aureus

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

ANI Pharmaceuticals 5 patents Pfizer 3 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating osteomyelitis due to staphylococcus aureus. Each bar = one year. Y-axis scaled to peak year (5 patents).

1
26
1
28
1
30
5
35
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vancocin
vancomycin
 ANI Pharmaceuticals 5 39 — 2035-11-06
Cleocin T
CLINDAMYCIN PHOSPHATE
 Pfizer 3 68 — 2026-12-02
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9789057 Cleocin T method of use 80 2026-12-02
8869794 Tobi method of use 75 2028-09-12
11129896 Cleocin T method of use 70 2036-09-22
10207066 Tobi method of use 68 2030-11-04
12303563 Cleocin T formulation 55 2036-09-22
11517609 Vancocin method of use 53 2035-11-06
10188697 Vancocin method of use 45 2035-11-06
10039804 Vancocin method of use 45 2035-11-06
11000567 Vancocin formulation 25 2035-11-06
10849956 Vancocin formulation 25 2035-11-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10849956 Vancocin formulation 25 2035-11-06
11000567 Vancocin formulation 25 2035-11-06
10188697 Vancocin method of use 45 2035-11-06
10039804 Vancocin method of use 45 2035-11-06
11517609 Vancocin method of use 53 2035-11-06
12303563 Cleocin T formulation 55 2036-09-22
10207066 Tobi method of use 68 2030-11-04
11129896 Cleocin T method of use 70 2036-09-22
8869794 Tobi method of use 75 2028-09-12
9789057 Cleocin T method of use 80 2026-12-02

Related